Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 0.7% – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares traded up 0.7% during mid-day trading on Friday . The company traded as high as $6.19 and last traded at $6.13. Approximately 7,806,536 shares were traded during mid-day trading, an increase of 17% from the average session volume of 6,678,073 shares. The stock had previously closed at $6.09.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.25.

Recursion Pharmaceuticals Trading Down 1.0 %

The stock has a market capitalization of $1.73 billion, a PE ratio of -3.94 and a beta of 0.85. The firm has a 50-day moving average price of $6.76 and a 200-day moving average price of $7.20. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the business earned ($0.43) earnings per share. The company’s revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total value of $71,200.34. Following the completion of the sale, the director now owns 7,098,428 shares of the company’s stock, valued at approximately $44,152,222.16. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock valued at $724,691 in the last ninety days. 15.75% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC increased its holdings in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after acquiring an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC boosted its stake in Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after purchasing an additional 1,800 shares during the period. Interchange Capital Partners LLC boosted its stake in Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after purchasing an additional 2,349 shares during the period. Amalgamated Bank boosted its stake in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.